28.49 -0.74 (-2.53%)
Pre-Market: 4:09AM EDT
|Bid||28.98 x 1000|
|Ask||29.29 x 900|
|Day's Range||28.12 - 29.23|
|52 Week Range||24.90 - 29.23|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 15, 2018 / MorphoSys AG (NASDAQ: MOR), (FSE: MOR), (XETRA: MOR) today announced the presentation of clinical data from the exploratory phase 2 COSMOS trial. ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 15, 2018 / MorphoSys AG (MOR), (MOR), (MOR.DE) today presented updated data from the ongoing phase 1/2a study of the anti-CD38 antibody MOR202 in relapsed/refractory multiple myeloma at the European Hematology Association (EHA) Annual Meeting 2018 in Stockholm. The dose escalation trial comprises three arms: MOR202, MOR202 in combination with the immunomodulatory drug (IMiD) lenalidomide (LEN), and MOR202 in combination with the IMiD pomalidomide (POM), in each case with low-dose dexamethasone (DEX). "We are optimistic about the responses seen in patients with multiple myeloma treated with MOR202 plus LEN/DEX and POM/DEX based on matured data as well as about the low proportion of patients experiencing infusion-related reactions," commented Dr. Malte Peters, Chief Development Officer of MorphoSys AG.
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 12, 2018 / MorphoSys AG (NASDAQ: MOR, OTC PINK: MPSYY, FSE: MOR, XETRA: MOR, Prime Standard Segment, TecDAX) announced today that the first patient has been enrolled in a new phase 3 trial of gantenerumab in patients with early Alzheimer's disease. Gantenerumab is a monoclonal antibody directed against amyloid-beta generated by MorphoSys using its proprietary HuCAL antibody technology. Roche is fully responsible for the clinical development of gantenerumab.
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 4, 2018 / MorphoSys AG (NASDAQ: MOR, OTC PINK: MPSYY, FSE: MOR, XETRA, MOR, Prime Standard Segment, TecDAX) will present at the following conferences: dbAccess ...
I am going to take a deep dive into MorphoSys AG’s (XTRA:MOR) most recent ownership structure, not a frequent subject of discussion among individual investors. The impact of a company’sRead More...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / May 18, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY; NASDAQ: MOR) will present at the following conferences: UBS Global Healthcare ...
At the AGM 2018 of MorphoSys AG, 60.69% of the current share capital was represented. After the AGM, the Supervisory Board in its inaugural meeting elected Dr. Marc Cluzel as its new Chairman and Dr. Frank Morich as Deputy Chairman.
NASDAQ: MOR) today announced the publication of two abstracts on its proprietary hemato-oncological drug candidates MOR208 and MOR202 submitted to the 23rd European Hematology Association (EHA) Annual Meeting, to be held in Stockholm/Sweden from June 14-17, 2018. In a poster presentation, first clinical data from the exploratory phase 2 COSMOS trial with the Fc-engineered CD19 antibody MOR208 in combination with idelalisib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), after discontinuation of an ibrutinib therapy, will be presented. In an oral presentation, updated maturing data from a phase 1/2a study with the CD38 antibody MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed/refractory multiple myeloma will be presented.
Conference call and webcast (in English) to be held on May 3, 2018, at 2:00pm CEST (1:00pm BST/8:00am EDT) - Successful capital increase and U.S. Nasdaq listing closed in April 2018 with total gross proceeds ...
OTC: MPSYY) and Galapagos NV (GLPG) announced today that the first patient has been enrolled in IGUANA, a phase 2 study with MOR106, an investigational antibody directed against IL-17C, in atopic dermatitis patients. At least 180 patients with moderate-to-severe atopic dermatitis (AD) are planned be treated over a 12-week period with one of three different doses of MOR106 (1, 3 or 10 mg/kg) or placebo using two different dosing regimens in this phase 2 trial in multiple centers across Europe. ''Moderate-to-severe AD is a chronic, debilitating disease affecting millions of patients worldwide,'' said Dr. Malte Peters, Chief Development Officer of MorphoSys AG.
NASDAQ: MOR) announced today that an affiliate of its licensee, Janssen Korea Ltd. (Janssen), reported that South Korea's Ministry of Food and Drug Safety has approved Tremfya(R) (guselkumab) for the treatment of moderate to severe adult plaque psoriasis requiring phototherapy or systemic therapies. Tremfya(R) is a fully human anti-IL-23 monoclonal antibody developed by Janssen Research & Development, LLC and was generated utilizing MorphoSys's proprietary HuCAL antibody library technology. MorphoSys is eligible to receive royalties on net sales of Tremfya(R).
PLANEGG/MUNICH, GERMANY PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 25, 2018 / Please note MorphoSys's updated financial reporting dates for the remainder of 2018. After the successful listing at ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 23, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY; NASDAQ: MOR) announced today the closing of its initial public offering ...
NEW YORK, April 19, 2018-- MorphoSys AG, a late-stage biopharmaceutical company devoted to the development of innovative and differentiated therapies for patients suffering from serious diseases, visited ...